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Abstract
Objective—Determine whether antenatal exposure to magnesium is associated with spontaneous 
intestinal perforation in extremely low birth weight infants (≤1000 g).
Study Design—We identified all extremely low birth weight infants admitted to one of 323 
neonatal intensive care units from 2007 to 2013. We used multivariable conditional logistic 
regression to compare outcomes in the first 21 days after birth between infants exposed and 
unexposed to magnesium in utero.
Results—Of the 28,035 infants, 11,789 (42%) were exposed to antenatal magnesium. There was 
no difference in the risk of spontaneous intestinal perforation, odds ratio=1.08 (95% confidence 
interval; 0.91–1.29), between infants exposed and unexposed to antenatal magnesium. Mortality in 
the first 21 days after birth was lower in the magnesium exposed infants, odds ratio=0.76 (0.70–
0.83).
Conclusion—Antenatal magnesium exposure in extremely low birth weight infants was not 
associated with increased risk of spontaneous intestinal perforation.
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INTRODUCTION
Antenatal magnesium (AM) has several uses including seizure prophylaxis for mothers with 
preeclampsia, tocolysis, and, most recently, neuroprophylaxis for premature infants.(1–7) 
AM is beneficial in stopping the progression from preeclampsia to eclampsia.(7) The 
evidence is inconclusive in regards to its use for tocolysis, with a systematic review 
concluding no benefit in preventing premature birth.(6) Over the past several years, there has 
been a growing body of evidence to suggest that AM is effective in improving neurologic 
outcomes in premature infants.(3, 5, 8)
Magnesium acts as an enzyme cofactor and is involved in the function of the ATPase 
sodium-potassium pump. Magnesium is also a central nervous system depressant and 
inhibits peripheral neuromuscular transmissions, impairing intestinal tract motility and 
function. Data are mixed on the effect of AM on the gastrointestinal system. A delay in first 
stool has been observed in premature infants exposed to AM for maternal preeclampsia in 
some studies(9), though not in others.(10–12) AM has not been shown to affect neonatal 
intestinal blood flow,(13) meconium plug syndrome,(14) or necrotizing enterocolitis (NEC).
(3, 5) However, the relationship between magnesium and spontaneous intestinal perforations 
(SIPs) has not been widely investigated.
At our institution, we observed an increased risk of SIPs in premature infants following the 
initiation of AM administration for neuroprophylaxis.(15) Here, we evaluated a large 
multicenter cohort to determine if AM exposure was associated with SIP or death in 
extremely low birth weight infants (ELBW, ≤1000 g birth weight).
SUBJECTS AND METHODS
Study Design and Setting
We used a database derived from electronic medical records generated by clinicians on all 
infants cared for by the Pediatrix Medical Group in 323 neonatal intensive care units 
(NICUs) in North America. Data on multiple aspects of care were entered into a shared 
electronic medical record to generate admission, daily progress notes, and discharge 
summaries. Information regarding maternal history, demographics, medications, laboratory 
results, diagnoses, and procedures was then transferred to the Pediatrix Clinical Data 
Warehouse for quality improvement and research purposes. [9] We included 28,035 ELBW 
infants discharged between 1997 and 2013. We excluded outborn infants and those with 
severe congenital anomalies. The study was approved by the Duke University Institutional 
Review Board.
Definitions and Participants
We defined AM exposure as an infant with AM exposure for any reason prior to delivery. 
The primary outcome was defined as the occurrence of a SIP in the first 21 days after birth. 
Secondary outcomes included the diagnoses of surgical or medical NEC, death, grade 3 or 4 
intraventricular hemorrhage (IVH), and the combined outcome of SIP, NEC, or death in the 
first 21 days after birth. We defined postnatal exposure to hydrocortisone or indomethacin/
ibuprofen as either exposure prior to an outcome, or exposure in the first 21 days after birth 
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if an infant did not experience an outcome. Given that the diagnoses of SIP and surgical 
NEC sometimes overlap, an infant who was diagnosed with both had the episode classified 
as surgical NEC. Likewise, if an infant had both medical NEC and surgical NEC diagnoses, 
the episode was classified as surgical NEC.
Statistical Methods
The unit of observation for this analysis was the infant. We compared demographic 
distributions among infants with and without AM exposure using Fisher’s exact test. We 
used conditional logistic regression conditioned on site to account for the clustered nature of 
the data to evaluate the association between AM exposure and the outcomes of SIP, NEC, 
death, IVH or the combined outcome of SIP, NEC or death. All models were adjusted for 
gestational age at birth, multiple gestation, antenatal steroid exposure, antenatal antibiotic 
exposure, prolonged rupture of membranes, small for gestational age, gender, postnatal 
hydrocortisone exposure, postnatal indomethacin exposure, and year. STATA 14 (College 
Station, TX) was used to perform the statistical analysis. For inquiries into the availability of 
the code please contact the corresponding author. A p<0.05 was considered statistically 
significant for all tests.
RESULTS
Of 28,035 ELBW infants admitted to the NICU during the study period, 11,789 (42%) were 
exposed to AM (Table 1). Demographic characteristics were similar between those exposed 
and unexposed to AM, except for the administration of antenatal steroids (94% in AM group 
versus 70% in unexposed group) and antenatal antibiotics (55% in AM group versus 35% 
unexposed group [Table 1]). The median birth weight for infants exposed and not exposed to 
AM was 775 g (25th, 75th%tile; 650, 890) and 767 g (630, 890). The median gestational age 
for infants exposed to AM was 26 weeks (25th, 75th%tile; 25, 27) and not exposed to AM 
was 26 weeks (24, 27). Use of AM increased over time; 28% of ELBW infants were 
exposed to AM in 2007, and 56% of ELBW infants were exposed in 2013.
There were a total of 710 infants with SIPs, 340/11,789 (2.9 %) in the AM exposed and 
370/16,246 (2.3%) in the unexposed group. Of the 710 infants with SIPs, 73% were ≤ 26 
weeks gestational age. There was no significant difference in the adjusted odds of SIPs 
between infants exposed and unexposed to AM, odds ratio =1.08 (95% confidence interval; 
0.91–1.29). Given recent concerns about misclassification of subjects with both SIP and 
surgical NEC diagnoses, we performed an additional analysis where all infants with both 
diagnoses were classified as a case of SIP.(16) This yielded similar results with an odds ratio 
of 1.05 (95% confidence interval; 0.89–1.50). Results were similar when adjusted analyses 
was repeated after excluding infants with unknown survival status at hospital discharge, odds 
ratio=0.98 (0.80–1.19). There were a total of 3887 infant deaths in the first 21 days after 
birth and infants exposed to AM had lower mortality, odds ratio=0.76 (0.70–0.83) (Table 2). 
There was no difference in medical NEC, surgical NEC, or IVH between the 2 groups.
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DISCUSSION
Current obstetrical practice is to use AM for seizure prophylaxis in preeclampsia, tocolysis, 
and most recently, neuroprophylaxis for mothers at imminent risk of premature delivery. 
With this new indication, increasing numbers of premature infants are exposed to AM. At 
our institution we noticed an increase in SIP in ELBW infants after the initiation of 
magnesium for neuroprophylaxis, a complication that, to our knowledge, has not been 
described in the literature.(15) In the present study, 11,789 of 28,035 (42%) ELBW infants 
were exposed to AM. We did not observe an association between AM exposure and SIPs in 
ELBW infants.
SIP is recognized as an entity separate from NEC. The pathophysiology of SIP is not fully 
understood; possible causes include decreased gastrointestinal perfusion, thinning of the 
intestinal lining, and administration of certain medications such as steroids or indomethacin.
(17) SIP is most common in ELBW infants, with an incidence ranging from 2.2% to 8.4%.
(18–20) At our institution, we examined the risk of SIP before and after initiation of routine 
AM neuroprophylaxis protocol, after noting a cluster of perforations among our ELBW 
infants. Prior to the AM neuroprophylaxis protocol, 51% of the ELBW infants were exposed 
to AM compared to 78% after its implementation. The incidence of SIPs in ELBWs 
increased from 12% to 30% (p=0.09) with the implementation of AM use for 
neuroprophylaxis.(15) This observation led us to conduct this multicenter retrospective study 
evaluating the association between SIP and AM exposure across the Pediatrix network. The 
incidence of SIP in this cohort (2.5%) was on the lower side of the range reported in the 
literature (18–20) and we found no difference in the adjusted risk of SIP between infants 
exposed and unexposed. Uncontrolled or unknown causes of SIP may explain the different 
results between these cohorts.
Unlike SIP, NEC has been a commonly reported outcome in trials investigating the use of 
AM magnesium for neuroprophylaxis. Several randomized control trials showed no 
significant difference in the incidence of NEC between placebo and AM treatment groups.
(3, 5, 8) Our findings are consistent with these previous studies, showing no increase in 
NEC. However, when interpreting these data, there is the possibility that some infants with 
NEC were transferred to other centers for more specialized or surgical care prior to their 
NEC diagnosis, which may decrease the total number of NEC cases in this cohort.
IVH may increase the risk of cerebral palsy,(21–24) which could influence the 
neuroprotective effect of magnesium. Previous reports showed no difference in IVH in 
infants exposed to AM versus those unexposed.(3, 5, 8, 25, 26) This study supports the 
previous literature with no significant difference in IVH between the two groups.
The initial randomized controlled study to evaluate the use of AM to decrease cerebral palsy 
was stopped prior to completion due to an increase in total pediatric deaths in the group 
exposed to high doses of magnesium (greater than 50 grams) (risk difference 15.2%; 95% CI 
4.4–26.0, p=0.01).(27) However, none of the 3 completed randomized controlled studies had 
a significant increase in deaths.(3, 5, 8) It should be noted that these 4 studies all used 
different magnesium doses, with the study that ended prematurely using some of the highest 
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doses.(3, 5, 8, 27) In our study, we saw a decrease in death in the first 21 days after birth in 
the exposure group (5.7% versus 8.2%, p<0.05). This finding should be interpreted with 
caution, as we do not have any data on dosing, timing, or indication for AM treatment. 
Additionally, 9.9% of our cohort had missing death data. Further investigation is required to 
better define the relationship between AM exposure, death, and dosing.
This is the largest study to report on the use of AM in ELBW infants, and the only one to 
our knowledge to examine the association of AM with SIPs. Strengths of this study include 
population diversity from academic and community institutions, ability to adjust for multiple 
potential confounders, and a contemporary study period. Our results are generalizable to 
young infants admitted to a NICU following AM exposure.
This study has several limitations including its retrospective design, the inability to 
determine the indication for AM administration, the total dose administered, magnesium 
levels of the mother and infants, and timing of the magnesium administration in relation to 
birth. There may be differences in outcomes depending on indication. For example, infants 
born to mothers receiving AM for seizure prophylaxis often have placental insufficiency and 
growth retardation. This may alter their risk of SIP compared to infants exposed to AM for 
neuroprophylaxis. Another limitation is the lack of data once an infant is transferred to 
another hospital outside of the Pediatrix network. Outcomes such as SIP, NEC, or death may 
be missed on these infants. Therefore, the results need to be interpreted with caution.
In this large multicenter study we observed no significant difference in SIP, NEC, or IVH 
between those infants exposed to AM and those unexposed. We did report a significant 
decrease in death in the first 21 days after birth, though that data had a large amount of 
missing data. Future investigations should prospectively investigate the role of AM on SIPs, 
and examine the role of AM dosing on infant outcomes.
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Table 1
Demographics
Magnesium exposed(%)
N=11,789
Unexposed (%)
N=16,246
Gestation (weeks)
 < 26    5165 (44%)    7346 (45%)
 26–28    5400 (46%)    6781 (42%)
 ≥ 29    1224 (10%)    2109 (13%)
Birth weight (g)
 ≤ 750    5374 (46%)    7683 (47%)
 751–1000    6415 (54%)    8563 (53%)
Race/Ethnicity
 White    4902 (42%)    6442 (40%)
 Black    3892 (33%)    5187 (32%)
 Hispanic    2011 (17%)    3151 (19%)
 Other      647 (5%)      845 (5%)
Multiple gestation    2072 (18%)    2576 (16%)
Male    5802 (49%)    8080 (50%)
PROM    1579 (13%)    2467 (15%)
Antenatal steroids 11,098 (94%) 11,336 (70%)
Antenatal antibiotics    6451 (55%)    5697 (35%)
Postnatal hydrocortisone      888 (8%)    1374 (8%)
Postnatal indomethacin    2369 (20%)    3045 (19%)
PROM: prolonged rupture of membranes
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Table 2
Outcomes in the magnesium exposed and unexposed group *p<0.05
Magnesium
N=11,789
No Magnesium
N=16,246
Adjusted OR**
(95% CI)
SIP   340 (2.9%)   370 (2.3%) 1.08 (0.91, 1.29)
Death 1338 (11.4%) 2549 (15.7%) 0.76 (0.70, 0.83)*
Surgical NEC   143 (1.2%)   253 (1.6%) 0.84 (0.66, 1.05)
Medical NEC   191 (1.6%)   270 (1.7%) 1.11 (0.89, 1.37)
Death, NEC, or SIP 1882 (16.0%) 3248 (20.0%) 0.84 (0.77, 0.90)*
IVH (Grade 3 or 4) 1219 (10.3%) 1889 (11.6%) 0.97 (0.88, 1.06)
CI: confidence interval; IVH: intraventricular hemorrhage; NEC: necrotizing enterocolitis; SIP: Spontaneous intestinal perforation; OR: odds ratio
**
adjusted for site, gestational age at birth, multiple gestation, antenatal steroid exposure, antenatal antibiotic exposure, prolonged rupture of 
membranes, small for gestational age, sex, discharge year, postnatal hydrocortisone exposure, and postnatal indomethacin exposure
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